

## **CRITICAL OUTCOME TECHNOLOGIES TO PRESENT AT 13<sup>TH</sup> ANNUAL BIO INVESTOR FORUM ON TUESDAY, OCTOBER 7, 2014**

### ***Significant impact of COTI-2's p53-dependent mechanism of action on cancer to be highlighted***

**London, Ontario (October 6, 2014):** Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX Venture: COT; OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President and Chief Executive Officer, will be presenting at the 13th Annual BIO Investor Forum being held October 7-8, 2014 at the Palace Hotel in San Francisco, California. The annual BIO Investor Forum is hosted by the Biotechnology Industry Organization (BIO) and features leading private and emerging public companies.

Dr. Danter is scheduled to present on Tuesday, October 7, 2014, at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) in the Sea Cliff Room at the Palace Hotel. In addition to providing an overview of the Company, Dr. Danter's presentation will focus on the Company's lead cancer drug candidate, COTI-2, which has a p53-dependent mechanism of action and which recently received the Orphan Drug Designation from the United States Food and Drug Administration for the treatment of ovarian cancer.

The presentation will be available on the Company's blog at [www.criticaloutcomeblog.com/blog-posts](http://www.criticaloutcomeblog.com/blog-posts) and on SlideShare at [www.slideshare.net/CriticalOutcome](http://www.slideshare.net/CriticalOutcome).

#### **About Critical Outcome Technologies Inc.**

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules – dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS<sup>®</sup>, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit [www.criticaloutcome.com](http://www.criticaloutcome.com) or contact:

Critical Outcome Technologies Inc.

Dr. Wayne Danter

President & CEO

Tel: 519-858-5157

Email: [wdanter@criticaloutcome.com](mailto:wdanter@criticaloutcome.com)

Heisler Communications

Trevor Heisler

Investor Relations

Tel: 416-500-8061

Email: [trevor@heislercommunications.com](mailto:trevor@heislercommunications.com)

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*